https://www.selleckchem.com/pr....oducts/trastuzumab-e
People with concomitant human immunodeficiency virus (HIV) and tuberculosis (T have an increased risk of hepatotoxic reactions due to antiretroviral therapy (ART) and anti-TB therapy (ATT). Concomitant hepatitis B virus (HBV) in these patients may lead to poorer health outcomes. To assess liver enzyme levels and immune response in adults with HIV, HBV, and TB, data from 300 antiretroviral-naïve people living with HIV (PLWHIV) were analyzed. The prevalence of HIV/HBV (cHIV/HBV) and HIV/TB (cHIV/T was 28% (95% CI
Like
Comment
Share
